Senior Director, US Medical Affairs Strategy Lead - GI

Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development.

Requirements

• Develops and executes the USMA strategy and medical objectives including activities related to scientific engagement and communication, evidence generation, internal education, and patient advocacy.
• Develops and executes a Health Care Professional (HCP) engagement strategy to gather insights to inform the medical strategy.
• Acts as the US medical representative on cross-functional teams.
• Serves as a therapeutic area content expert.
• Participates in the Global Medical Affairs Team (GMAT) and US Medical Affairs Team (USMAT) to execute medical strategies, contribute to the operations and oversight of medical activities, and work cross-functionally to support associated pre-launch activities.

Benefits

• Competitive cash compensation
• Robust equity awards
• Strong benefits
• Significant learning and development opportunities